Amgen Licenses Nanopartical Technology to Improve Cancer Drug

Amgen (NASDAQ: AMGN  ) is licensing BIND Biosciences' Medicinal Nanoengineering platform called Accurins to make its cancer drug better.

The technology surrounds a drug with a protective coat, which allows the drug to avoid detection by the immune system. Targeting ligands that can deliver the nanoparticle to a specific tissue are attached to the protective coat. The nanoparticles also allow for controlled-release of the drug once it gets to the tumor. Amgen plans to combine the technology with an undisclosed proprietary kinase inhibitor to attack solid tumors.

BIND and Amgen will work together on preclinical development, and then Amgen will be responsible for the clinical development and commercialization of the drug.

Amgen could owe BIND up to $46.5 million in up-front and development milestone payments. Once the drug is approved, there's potential for an additional $134 million in regulatory and sales milestone payments for the first tumor type. Bind is also eligible for additional payments and tiered royalties on future sales if the drug makes it to market.

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2184939, ~/Articles/ArticleHandler.aspx, 10/31/2014 4:49:04 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement